http://www.fresenius.com en-us Thu, 20 Feb 2020 00:00:00 +0100 Thu, 20 Feb 2020 00:00:00 +0100 Thu, 20 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius reports 16th consecutive record year - Significant investments into growth – Healthy growth for 2020 expected – Medium-term growth targets confirmed]]> - Good organic sales growth across all business segments
- Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America
- Fresenius Helios shows continued stabilization in Germany and strong growth in Spain
- Fresenius Medical Care expects to show strong growth in 2020
- 27th consecutive dividend increase proposed

]]>
Thu, 20 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi and Vifor Pharma create joint venture in China for i.v. iron portfolio ]]> Fresenius Kabi and Vifor Pharma have formed a joint venture in China to provide patients access to vital blood management treatment. It will combine Vifor Pharma’s leading intravenous drug portfolio for the treatment of iron deficiency with Fresenius Kabi’s strong and long-year presence in the market to benefit both patients and the healthcare system in China. The joint venture will focus on marketing, market access and medical affairs activities whereas Fresenius Kabi will be fully responsible for the commercialization of the intravenous iron portfolio. The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Financial terms were not disclosed.

]]>
Wed, 19 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Helios acquires first hospital in Bogotá, continuing expansion in Colombia’s private hospital market]]> Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Clínica de la Mujer in Bogotá, further expanding the company’s presence in Colombia’s attractive private hospital market.

]]>
Wed, 05 Feb 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi diversifies U.S. product portfolio]]> With the launch of a Glucagon Emergency Kit, Fresenius Kabi offers an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes. This is the company’s first pharma product sold and used primarily outside hospitals in the U.S.

]]>
Tue, 21 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi enters into joint venture to advance new cell and gene therapies]]> Fresenius Kabi, Bio-Techne and Wilson Wolf have formed a new joint venture to support researchers and biopharmaceutical companies in the field of cell and gene therapy. The joint venture is owned equally by the three partners and will focus on providing scalable manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies. No other financial terms were disclosed.

]]>
Thu, 16 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius Helios trains doctors in antibiotics management]]> Fresenius Helios has started training experts in antibiotics management to combat the growing threat from multi-resistant bacteria. In the coming years, more than 600 doctors will be trained at the company’s 86 hospitals in Germany on the correct way to handle antibiotics. These doctors will raise awareness of the problem among colleagues and be available for consultations with them. In addition, Fresenius Helios is introducing a system under which each hospital will report on its antibiotics usage.

]]>
Tue, 07 Jan 2020 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of 750 million euros]]> Fresenius today successfully placed bonds with a volume of €750 million.

]]>
Mon, 23 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Helios acquires leading private hospital in Colombia]]> Quirónsalud, the largest private hospital group in Spain and part of Fresenius Helios, has signed an agreement to acquire Centro Médico Imbanaco (CMI) in Cali, further expanding the company’s presence in Colombia’s attractive private hospital market.

]]>
Fri, 20 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Busulfan, a drug for certain blood cancers, expands the company’s broad oncology portfolio.

]]>
Thu, 19 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Dicyclomine Hydrochloride Injection, an antispasmodic agent, expands Fresenius Kabi’s large and growing generic critical care portfolio.  

]]>
Wed, 11 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Ertapenem, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.

]]>
Tue, 10 Dec 2019 08:00:00 +0100 <![CDATA[Fresenius Helios awards new innovation prize]]> Fresenius Helios has awarded its inaugural Helios-Pro-Inno Prize for outstanding innovation and projects in patient care and hospital management. Three different projects at Helios Wuppertal, Helios Berlin-Buch and Helios Bad Saarow hospitals in Germany were honored: A color and lighting concept that demonstrably improved the well-being of intensive care patients and even reduced their need for certain medications; the appointment of a “Feel Good Manager” for resolving employees’ problems in the workplace, and an antibiotics reporting system developed in response to the growing threat from multi-resistant bacteria. A jury of eight members, from different occupational groups, chose the Helios-Pro-Inno Prize winners from more than 70 entries.

]]>
Wed, 13 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Fosaprepitant, an antiemetic, expands the company's large sterile injectable portfolio in oncology.

]]>
Tue, 12 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed completes main university hospital building in Lübeck]]> After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Lübeck. Following the opening in August of the new main building at the UKSH’s other location, in Kiel, the modernization of Germany’s second-largest university hospital is now largely complete. In addition to the new construction and the comprehensive renovation of the two university hospital locations, the project includes their technical management through 2044. With a total volume of €1.7 billion, the UKSH modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

]]>
Tue, 05 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Vamed wins awards for spa and wellness facilities]]> VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2019” at the World Spa Awards. Four VAMED Vitality World facilities – Geinberg5 Private Spa Villas, St. Martins Therme & Lodge, Therme Laa Hotel & Spa and la pura women’s health resort – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria.

]]>
Mon, 04 Nov 2019 08:00:00 +0100 <![CDATA[Fresenius Helios acquires medical diagnostics provider in Colombia ]]> Quirónsalud, Spain’s largest private hospital group and part of Fresenius Helios, has acquired CediMed, a leading medical diagnostics group in Colombia.

]]>
Tue, 29 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius confirms guidance after solid third quarter]]> Strong organic sales growth across all business segments - Growth investments proceeding according to plan - Fresenius Kabi’s excellent Emerging Markets growth partially offsets softer development in North America - Fresenius Helios showing excellent organic sales growth across all regions - Fresenius Medical Care with record growth in home dialysis in North America

]]>
Fri, 25 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches new Heparin Sodium in prefilled syringe in the U.S.]]> A new presentation of Fresenius Kabi Heparin is now available in the company’s Simplist® ready-to-administer prefilled syringe, expanding the company's Heparin portfolio.

]]>
Wed, 23 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi expands plant in Brazil]]> Fresenius Kabi has completed the expansion of its plant in Aquiraz, Brazil, increasing the facility’s capacity for parenteral nutrition production by around 30 percent. The company expects to hire about 50 new employees to bring the plant’s workforce to about 850. Fresenius Kabi, which has been active in Brazil for more than 40 years, invested some €20 million in the expansion and modernization of the Aquiraz plant.

]]>
Mon, 07 Oct 2019 08:00:00 +0100 <![CDATA[Fresenius Kabi launches Fulvestrant in prefilled syringes in the U.S.]]> Fulvestrant Injection is now available in the United States in the company’s ready-to-administer prefilled syringes and is the latest addition to Fresenius Kabi’s broad oncology portfolio. The product is the only room temperature stable Fulvestrant Injection currently available in the U.S.

]]>